Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma

Cancer

Volumn 94, Issue 12, 2002, Pages 3141-3149

  Sinha, Akhouri A ^a,d   Quast, Barry J ^a   Wilson, Michael J ^a,b,c   Fernandes, Eduardo T ^a,c   Reddy, Pratap K ^c   Ewing, Stephen L ^b,c   Gleason, Donald F ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Research Service   (United States)

Author keywords

Aggressive and less aggressive clones; Aggressive cancer with lymph node metastasis; Cathepsin B; Molecular markers; Prostate carcinoma; Ratios of cathepsin B to stefin A; Stefin (cystatin) A; Subpopulations of tumors within a Gleason score

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CATHEPSIN B; STEFIN A;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CELL SUBPOPULATION; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MOLECULAR CLONING; MOLECULAR WEIGHT; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN LOCALIZATION; SEMINAL VESICLE; TISSUE SECTION;

AGED; CATHEPSIN B; CYSTATINS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS;

EID: 0037096882     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10604     Document Type: Article

References (46)

1. Prognostic factors in prostate cancer
2. Classification of prostatic carcinomas
3. Histologic grading and clinical staging of prostatic carcinoma
4. Histologic grading of prostate cancer
5. Classification of "localized" untreated prostate cancer based on 791 men treated only by radical prostatectomy: Common ground for therapeutic trials and TNM subgroups
6. Prostate cancer in men age 50 years or younger: A review of the department of defense center for prostate disease research multicenter prostate cancer data base
7. Natural history of progression after PSA elevation following radical prostatectomy
8. Competing risk analysis of men aged 55 to 74 years at diagnosis man aged conservatively for clinically localized prostate cancer
9. Prostate cancer mortality in patients surviving more than 10 years after diagnosis
10. The challenge of locally advanced prostate cancer
11. Biological determinants of cancer progression in men with prostate cancer
12. Ability to predict biochemical progression using Gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei
13. Pathology of prostatic intraepithelial neoplasia and adenocarcinoma of the prostate: Prognostic influences of stage, tumor volume, grade, and margins of resection
14. An enhanced prognostic system for clinically localized carcinoma of the prostate
15. Future prospects in prostate cancer
16. Chemotherapy of advanced prostatic carcinoma
17. Novel molecular targets for prostate cancer therapy
18. Immunohistochemical localization of cathepsin B in neoplastic human prostate
19. The relationship of cathepsin B and stefin A mRNA localization identifies a potentially aggressive variant of human prostate cancer within a Gleason histologic score
20. Co-distribution of pro and mature cathepsin B forms in human prostate tumors detected by confocal and immunofluorescence microscopy
21. Plasma membrane association of cathepsin B in human prostate cancer: Biochemical and immunogold electron microscopic analysis
22. Cathepsin B and its endogenous inhibitors: Role in tumor malignancy
23. Immunocytochemical and immunoelectron microscopic demonstration of cathepsin B in human malignant melanoma
24. Immunochemical analysis of cathepsin B in lung tumours: An independent prognostic factor for squamous cell carcinoma patients
25. Molecular regulation, membrane association and secretion of tumor cathepsin B
26. Emerging roles for cysteine proteases in human biology
27. Cathepsin B and human tumor progression
28. Tumor cell membrane cathepsin B
29. Cathepsin B expression in human tumors
30. Is altered localization of cathepsin B casually related to malignant progression?
31. Membrane association of cathepsin B can be induced by transfection of human breast epithelial cells with c-Ha-ras oncogene
32. The ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer
33. Delineation of prognostic biomarkers in prostate cancer
34. The value of serum prostate specific antigen determinations before and after radical prostatectomy
35. A guide to the interpretation of serum prostate specific antigen levels
36. The relationship of prostate specific antigen levels and residual tumor volume in stage A prostate cancer
37. Extraction and analysis of diagnostically useful proteins from formalin-fixed, paraffin-embedded tissue sections
38. Localization of cathepsin B in normal and hyperplastic human prostate by immunoperoxidase and protein A gold techniques
39. Prostate cancer
40. Cathepsin B and cystatins: Evidence for a role in cancer progression
41. Cysteine prtoteinase inhibitor cystatin A in breast cancer
42. A critical analysis of tumor morphology and hormone treatments in the untreated and estrogen-treated responsive and refractory human prostatic carcinoma
43. An analysis of watchful waiting for clinically localized prostate cancer
44. Results of conservative management of clinically localized prostate cancer
45. Long-term survival among men with conservatively treated localized prostate cancer
46. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden